Showing 4661-4670 of 8849 results for "".
- Dermatology Hall of Fame to Recognize Industry Pioneershttps://practicaldermatology.com/news/dermatology-hall-of-fame-to-recognize-industry-pioneers/2459941/The Dermatology Hall of Fame will honor its first inductees February 28, 2019, in Washington, DC. The organization, founded in 2018, was established to recognize and honor past and present luminaries within all areas of dermatology. “The field of dermatology has been furthered by tr
- LEO Pharma Focuses on Translational Medicine, Appoints Dr. Adam B. Raff as Director & Medical Advisorhttps://practicaldermatology.com/news/leo-pharma-strengthens-focus-on-translational-medicine-with-appointment-of-dr-adam-b-raff-as-director-medical-advisor/2459942/LEO Pharma has appointed Adam B. Raff, MD, PhD as Director and Medical Advisor in Translational Medicine, effective January 28. Dr. Raff’s primary objective will be to support LEO Pharma’s ambitions to advance science within dermatology through translational medicine, the company says
- AD, Suicidal Thoughts and Attempts Linkedhttps://practicaldermatology.com/news/ad-suicidal-thoughts-and-attempts-linked/2457543/Patients with eczema may be more likely to have suicidal thoughts and attempts compared to their counterparts without eczema, according to a new study in JAMA Dermatology. Res
- SENTE Launches Collaborations with Galderma, The HydraFacial Companyhttps://practicaldermatology.com/news/sente-launches-collaborations-with-galderma-the-hydrafacial-company/2457546/New strategic collaborations are intended to broaden the reach of SENTÉ and further expand their disruptive professional grade skin care product portfolio, the company says. Both collaborations will offer consumers the opportunity
- Sinclair Pharma Announces Leadership Changeshttps://practicaldermatology.com/news/sinclair-pharma-announces-leadership-changes/2457491/Sinclair Pharma Limited reported that effective at the end of the year, Doug Abel has resigned his position as Head of North America and President of Silhouette Lift, Inc., to lead a new aesthetic venture and has licensed the US sales and marketing rights to the Refine Support System from Sinclai
- Exuviance Introduces HA100 Micro-Filler Regimenhttps://practicaldermatology.com/news/exuviance-introduces-ha100-micro-filler-regimen/2457502/Exuviance is launching HA100 Micro-Filler Regimen, a two-step beauty regimen featuring new Micro-Cone Patches that delivers 1
- Sonoma Pharmaceuticals Launches New Ceramax Skin Barrier Lotionhttps://practicaldermatology.com/news/sonoma-pharmaceuticals-launches-new-ceramax-skin-barrier-lotion/2457504/Sonoma Pharmaceuticals, Inc. has launched a new Ceramax™ Skin Barrier Lotion that complements Sonoma’s current Ceramax Skin Barrier Cream. Both Ceramax products contain skin-enriching technology that helps manage dry itchy skin,
- Cutanea Life Sciences Launches Xepi Creamhttps://practicaldermatology.com/news/cutanea-life-sciences-launches-xepi-cream-1/2457512/Cutanea Life Sciences, Inc. has launched Xepi™ (ozenoxacin) Cream, 1% for the treatment of impetigo in adult and pediatric patients two months of age or older. Xepi is a non-fluorinated topical quinolone indicated for the treatment of impetigo due to Staphylococcus aureus
- Ortho Dermatologics Gears Up to Launch Bryhali Lotion for Plaque Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-gears-up-to-launch-bryhali-lotion-for-plaque-psoriasis/2457514/Ortho Dermatologics expects to start distribution of Bryhali (halobetsasol propionate) Lotion, 0.01%, to U.S. wholesale pharmaceutical distributors later this month. The company received final approval from the U.S. Food and Drug Administration (FDA) for Bryhali Lotion on Nov. 6, 201
- FDA Approves Galderma's Restylane Lyft for Midface Injection Via Cannulahttps://practicaldermatology.com/news/fda-approves-galdermas-restylane-lyft-for-midface-injection-via-cannula/2457518/The U.S. Food and Drug Administration (FDA) has approved the use of Galderma’s Restylane Lyft with a small, blunt-tip cannula for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. This approval is the second ca